For research use only. Not for therapeutic Use.
Olcegepant（Cat No.:I002580）is a selective and potent antagonist of the CGRP (calcitonin gene-related peptide) receptor, a key player in the pathophysiology of migraines. By blocking the CGRP receptor, olcegepant helps to reduce the vasodilation and neurogenic inflammation associated with migraine attacks. It has been studied for its ability to treat acute migraines, offering a potential alternative to traditional triptan medications. Clinical trials have shown promise in terms of efficacy, with olcegepant providing migraine relief without some of the side effects seen with other treatments. Ongoing studies are assessing its long-term safety and effectiveness.
| Catalog Number | I002580 |
| CAS Number | 204697-65-4 |
| Synonyms | N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide |
| Molecular Formula | C38H47Br2N9O5 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | DMSO: ≥ 50 mg/mL |
| Storage | Store at -20°C |
| IC50 | 0.03 nM |
| IUPAC Name | N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide |
| InChI | InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1 |
| InChIKey | ITIXDWVDFFXNEG-JHOUSYSJSA-N |
| SMILES | C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6 |
